Ocugen is a high-risk, binary gene therapy option where clinical success could transform a $1 stock into a multibagger—but failure could leave shareholders nearly wiped out.
Overview
Ocugen is a clinical-stage ophthalmic gene therapy company with no commercial product revenue but a potentially disruptive pipeline targeting blindness. Its lead assets—OCU400 for broad Retinitis Pigmentosa, OCU410 for Geographic Atrophy, and OCU410ST for Stargardt disease—use gene-agnostic modifier biology rather than narrow mutation-specific replacement. The investment case is highly binary: successful approvals could unlock multibillion-dollar markets, while clinical, regulatory, manufacturing, competitive, and dilution risks remain severe.